SCHEMBL5419864

SCHEMBL5419864

O=C1CCCN1CCN1CCC(CN2CCc3cncc4cccc2c34)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRA1B P35368 5/20 0.42
ADRA1A P35348 3/20 0.42
ADRA1D P25100 2/20 0.42
KDM4E B2RXH2 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ACHE P22303 1/20 0.39
HTR2A P28223 5/20 0.38
HTR7 P34969 4/20 0.38
LTA4H P09960 2/20 0.37
HRH3 Q9Y5N1 1/20 0.37
HTR1A P08908 2/20 0.36
DRD2 P14416 2/20 0.36
HTR6 P50406 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5412476 0.97 ACHE (0.42) ADRA1BADRA1AADRA1DKDM4EL3MBTL1
SCHEMBL5410015 0.85 ADRA1B (0.43) ADRA1BADRA1AADRA1DACHEHTR2A
SCHEMBL5412606 0.83 ADRA1B (0.40) ADRA1BADRA1AADRA1DACHEHTR2A
SCHEMBL5417889 0.82 ADRA1B (0.40) ADRA1BADRA1AADRA1DKDM4EL3MBTL1
SCHEMBL5412392 0.82 ADRA1B (0.39) ADRA1BADRA1AADRA1DACHEHTR2A
SCHEMBL5596416 0.81 NOTUM (0.37) HTR2AHTR7HTR1ADRD2HTR6
SCHEMBL5425309 0.81 HTR2A (0.37) ADRA1BADRA1AADRA1DHTR2AHTR7
SCHEMBL5414854 0.80 ACHE (0.40) ADRA1BADRA1AADRA1DACHEHTR2A
SCHEMBL5419598 0.79 ACHE (0.37) ADRA1BADRA1AADRA1DACHEHTR2A
SCHEMBL5415185 0.79 KDM1A (0.39) ACHEHRH3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7160894-B2 Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine ASAHI KASEI PHARMA CORPORATION (JP) 2007-01-09 US disclosed
EP-1632492-A1 TRICYCLIC COMPOUND Asahi Kasei Pharma Corporation (JP) 2006-03-08 EP disclosed
US-20050096310-A1 Tricyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096310-A1 Tricyclic compound MYLK3, CSNK1A1L, MYLK ADRA1B 296/4885ADRA1A 119/4885ADRA1D 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.